Financial Performance - Total revenues for Q2 2024 reached 681.3million,a47.3462.4 million in Q2 2023[20] - Earned premiums for Q2 2024 were 674.1million,up47.5456.9 million in Q2 2023[20] - Medical expenses for Q2 2024 totaled 605.3million,representinga47.3410.6 million in Q2 2023[20] - The net loss for Q2 2024 was 24.0million,slightlyimprovedfromanetlossof28.5 million in Q2 2023[20] - Adjusted EBITDA for the three months ended June 30, 2024, was 6,034,000,asignificantimprovementof393.62,055,000 in the same period of 2023[157] - The loss from operations for the three months ended June 30, 2024, was 18,382,000,a22.323,659,000 in the same period of 2023[157] - Net cash provided by operating activities for the six months ended June 30, 2024, was 17,291,000,asignificantdecreasefrom122,287,000 for the same period in 2023[33] - The company recorded a net change in cash of 136.1millionforthesixmonthsendedJune30,2024,comparedtoadecreaseof14.3 million for the same period in 2023[196] Assets and Liabilities - Total current assets increased to 599.1millionasofJune30,2024,comparedto483.5 million at December 31, 2023, reflecting a 23.9% growth[18] - Total liabilities rose to 591.5millionasofJune30,2024,upfrom433.8 million at December 31, 2023, indicating a 36.3% increase[18] - The company reported a total stockholders' equity of 124.8millionasofJune30,2024,downfrom158.1 million at December 31, 2023[18] - The company’s total assets as of June 30, 2024, were 1,074,303,000,comparedto1,007,794,000 as of June 30, 2023, reflecting an increase of approximately 6.6%[29] Membership and Market Expansion - Health plan membership increased to 175,100 as of June 30, 2024, representing a 56.1% growth compared to 112,200 in the same period of 2023[157] - The company expanded into 14 new markets in 2023 and one new market in California in 2024, focusing on areas with significant senior populations[148] - The company holds a 4% market share in its existing 53 counties, indicating significant growth opportunities in the Medicare Advantage market[147] Expenses - Selling, general, and administrative expenses for Q2 2024 were 87.9million,a25.370.2 million in Q2 2023[20] - Medical expenses payable rose to 315,369millionasofJune30,2024,upfrom205,399 million as of December 31, 2023, indicating a 53.5% increase[99] - Total medical expenses incurred for the current year reached 407,156million,comparedto235,027 million for the same period in 2023, representing a growth of 73%[102] Cash Flow and Financing - Cash and cash equivalents at the end of the period on June 30, 2024, were 341,069,000,downfrom397,008,000 at the end of June 30, 2023, indicating a decrease of approximately 14.1%[35] - The company expects to require additional capital resources to execute strategic initiatives for growth, including technology development and market expansion[185][186] - The company had the option to borrow an additional 35.0millioninundrawnDelayedDrawTermLoans,whichexpiresonSeptember1,2025[190]RegulatoryComplianceandRisks−ThecompanywasincompliancewiththeminimumcapitalrequirementsprescribedbyregulatoryauthoritiesasofJune30,2024[132]−ThecompanycontinuestomonitorchangesinownershipthatcouldaffecttheutilizationofitssubstantialNOLsunderIRCSection382[116]TechnologyandFutureOutlook−Thecompanyaimstoleverageitsproprietarytechnologyplatform,AVA,toenhancememberrelationshipsandcarequality,whichisexpectedtodrivefutureperformance[146]−ThecompanyplanstocontinueinvestinginitsAVAplatformandpursuestrategicacquisitionstomaintainadifferentiatedvalueproposition[153]OtherFinancialMetrics−Thecompanyreportedaprovisionforcreditlossof95,000 for the six months ended June 30, 2024, compared to 51,000forthesameperiodin2023,showinganincreaseofapproximately86.32,460 million for the three months ended June 30, 2024, primarily due to better-than-expected claims recoveries[102]